Xenon Seven

Xenon Seven

Director/Senior Director, CMC, Drug Product Manufacturing (Late Stage/Commercial)

Boston · Director

Sponsorship not specifiedDetected 8 days ago
RESTSupply ChainClinical TrialsGMPFDA RegulatoryLeadershipCommunication

About the role

  • We are seeking a Director/Senior Director, CMC, Drug Product Manufacturing (Late Stage/Commercial) to join our team.
  • This position reports to the Executive Director, CMC, Drug Product and will be based out of our Boston, MA, USA in our Needham office or in our Burnaby, BC, Canada office.
  • We will consider other jurisdictions for exceptional candidates.

Responsibilities

  • Lead teams in late-stage process development and scale up, process validation (PPQ) and commercial manufacturing of small molecule drug products.
  • Manage development activities related to late-stage process development and scale up, FMEA analysis, process validation (PPQ) and preparation for commercial launch of small molecules drug products at partner CDMOs and CMO.
  • Manage on going commercial manufacturing and primary packaging of approved small molecule drug products by working with supply chain, quality and regulatory groups. Serve as CMC SME of commercial drug product supply.
  • Manage the selection of late-stage and commercial CDMOs while considering capabilities, capacities, redundancy and quality.
  • Evaluate, recommend, and manage qualified CDMOs for manufacturing drug products for late-stage clinical trials, scale-up, registration, validation and commercial use.
  • Collaborate with Quality Assurance to manage audits and inspections of CDMOs and on manufacturing investigations.
  • Author and review core CMC documents/modules and other submissions and responses to FDA and other Competent Authorities, ensuring strategic oversight and consistency for regulatory interactions, including IND/NDA/MAA/IMPD filings and periodic updates.
  • Develop and propose objectives in alignment with overall company strategies and plans.
  • Collaborate with development and commercial partnerships, including ex-US collaborations, to ensure global alignment and integration of strategies.
  • Plan and manage budget proposals and approved budgets in accordance with the Company's strategic and operating plans and Finance policies.

Requirements

  • PhD in Chemistry, Chemical Engineering, Pharmaceutical Sciences, Pharmaceutics, or a related discipline with at least 10 years of relevant management experience in a pharma or biotech environment.
  • Strong background in drug product manufacturing sciences with experience with multiple solid oral manufacturing approaches such as capsules, tablets, spray drying, granulation, blending, bottling and blistering.
  • In-depth knowledge of cGMP regulations, guidance, principles, and best practices related to drug product development and manufacture.
  • Proficiency in Failure Modes Effect Analysis (FMEA) and establishment of Critical Process Parameters (CPPs).
  • Experience with CDMO selection, management, contracting, and issue resolution.
  • Some domestic and international travel will be required.
  • PhD in Chemistry, Chemical Engineering, Pharmaceutical Sciences, Pharmaceutics, or a related discipline with at least 10 years of relevant management experience in a pharma or biotech environment. Candidates with an MSc and relevant experience may also be considered.
  • Extensive experience in managing late-stage drug product manufacturing and commercialization activities (registration, process scale up, validation and launch), including oversight of external Contract Manufacturing Organizations (CMOs).
  • Experience in developing formulations of small molecule solid oral and parenteral dosage forms is a plus.
  • Demonstrated success in transitioning development assets to commercial products and ongoing support of commercial manufacturing.
  • Experience contributing to and developing CMC sections in US and ex-US regulatory filings.
  • Excellent oral and written communication, leadership, and interpersonal skills, with the ability to build credibility and trust both inside and outside the company.
  • Proven ability to build and develop high-performing teams, with strong delegation and conflict resolution skills.
  • Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance programs, Employee Assistance Program, travel insurance, and retirement savings programs with company matching contributions.
  • Xenon encourages time to rest and re-charge through vacation, personal days, sick days, and an end-of-year company shutdown. Xenon highly values employee development and has an expanding Training, Learning & Development program, including a Tuition Assistance program for advanced degrees.

Compensation

  • Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance progr

Company info

  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • What We Do:
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
  • Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need.
  • We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
  • We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain.
  • Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
  • In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we anticipate submitting a New Drug Application to the Food and Drug Administration in the third quarter of 2026.
  • Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication.
  • We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial.
  • In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting.
  • We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are important pain targets.
  • Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
Apply directly at Xenon Seven →Create a free account for alerts like thisView Xenon Seven immigration profile

This listing is sourced directly from Xenon Seven's careers page and normalized into a canonical job model.